BETA-2-CROSSLAPS (CTX) Test Purpose

The Beta-2-CrossLaps (CTX) Test, also known as the C-Terminal Telopeptide (CTX) Test, measures the level of C-terminal telopeptide fragments of Type I collagen released into the bloodstream during bone breakdown (bone resorption). Since Type I collagen is the primary protein found in bones, CTX serves as a sensitive marker of bone resorption, helping healthcare providers evaluate the rate at which bone is being broken down.

Healthcare providers commonly recommend the CTX Test to assess individuals at risk of osteoporosis, monitor the effectiveness of osteoporosis treatment, and evaluate conditions associated with increased bone turnover. Furthermore, the test helps determine whether medications such as bisphosphonates, denosumab, or other anti-resorptive therapies are effectively reducing bone loss.

In addition, the Beta-2-CrossLaps (CTX) Test may be useful in the evaluation of postmenopausal osteoporosis, osteopenia, hyperparathyroidism, Paget’s disease of bone, and certain metabolic bone disorders. It can also assist in assessing fracture risk when interpreted alongside Bone Mineral Density (BMD) measurements and other bone turnover markers.

The test is often performed together with Vitamin D, Calcium, Phosphorus, Parathyroid Hormone (PTH), Bone-Specific Alkaline Phosphatase (BSAP), and DEXA scans to provide a comprehensive assessment of bone health.

BETA-2-CROSSLAPS (CTX) Test is Recommended for Individuals:

• Individuals at risk of osteoporosis or osteopenia.
• Postmenopausal women undergoing bone health evaluation.
• Patients receiving treatment for osteoporosis to monitor therapy effectiveness.
• Individuals with unexplained bone loss or recurrent fractures.
• Patients with hyperparathyroidism, Paget’s disease, or other metabolic bone disorders.
• Individuals with low bone mineral density (BMD).
• Patients requiring assessment of bone turnover before or during osteoporosis treatment.
• Individuals advised by their healthcare provider to undergo bone metabolism testing.

FAQs

1. What is the Beta-2-CrossLaps (CTX) Test used for?

The Beta-2-CrossLaps (CTX) Test measures a marker of bone resorption and helps evaluate how quickly bone is being broken down. It is commonly used to assess osteoporosis risk, monitor osteoporosis treatment, and evaluate metabolic bone disorders.

2. Do I need to fast before the Beta-2-CrossLaps (CTX) Test?

Yes. Fasting is generally recommended for the CTX Test because food intake and the time of sample collection can significantly affect CTX levels. The sample is usually collected in the morning after an overnight fast. Always follow your healthcare provider’s instructions before the test.

3. What does a high CTX level mean?

A high CTX level indicates increased bone resorption, meaning that bone is being broken down more rapidly than normal. This may be seen in osteoporosis, postmenopausal bone loss, hyperparathyroidism, Paget’s disease, or other conditions affecting bone metabolism. Your doctor will interpret the results together with your symptoms, bone density scan (DEXA), and other bone health tests to determine the underlying cause and appropriate treatment.